Effect of Pretransplant Use of Calcimimetic on Parathyroid Function after Renal Transplantation
Table 1
Patient characteristics before RT.
All
Calcimimetic
value
With
Without
n
74
27
47
Age, year
51 (18)
54 (16)
46 (21)
0.0703
Male, n
36 (49)
13 (48)
23 (49)
0.9479
BMI, kg/m2
21.5 (4.7)
21.3 (3.3)
21.5 (5.0)
0.7026
Underlying disease, n
IgA nephropathy
13 (18)
Other CGN
25 (34)
Type 1 DM
4 (5)
Type 2 DM
9 (12)
Nephrosclerosis
5 (7)
Others
15 (20)
Unknown
3 (4)
Duration of dialysis pretransplantation, year
3 (11)
12 (9)
1 (3)
<0.0001
Cadaveric donor kidney transplant, n
14 (19)
9 (33)
5 (11)
0.0184
History of DM, n
15 (20)
5 (19)
10 (21)
0.7753
History of HTN, n
46 (62)
16 (59)
30 (64)
0.6969
Smoking, n
17 (23)
4 (15)
13 (28)
0.1950
Alcohol, n
24 (33)
9 (33)
15 (32)
0.9002
Calcimimetic medication, n
27 (36)
Vitamin D medication, n
55 (74)
23 (85)
32 (68)
0.0949
Bisphosphonate medication, n
4 (5)
3 (11)
1 (2)
0.1065
Denosumab medication, n
0 (0)
0 (0)
0 (0)
BMD (YAM), %
87 (16)
88 (19)
86 (20)
0.5584
Intact PTH, pg/mL
215 (179)
209 (159)
241 (20)
0.6901
eGFR, ml/min/1.73 m2
3.9 (1.6)
3.4 (0.7)
4.4 (2.4)
0.0013
Adjusted ca, mg/dL
9.0 (1.0)
9.4 (0.6)
9.0 (0.9)
0.1193
IP, mg/dL
5.4 (2.1)
5.5 (1.7)
5.2 (2.7)
0.7492
Data are median (IQR, intraquartile range) for continuous variables and number (percent) for categorical variables. Bold values are those found to be significant; value <0.05. RT, renal transplantation; BMI, body mass index; DM, diabetes mellitus; HTN, hypertension; BMD, bone mineral density; YAM, young adult mean; PTH, parathyroid hormone; eGFR, estimated glomerular filtration rate.
